Major Finding: Age-associated changes in male fibroblasts induce a phenotypic switch to invasive and resistant melanoma.
Health Professionals
TH17 Cells May Serve as Biomarker in Metastatic Melanoma
TH17 cells may be a potential biomarker to predict the risk of immune-related adverse events in patients with metastatic melanoma receiving the combination therapy of nivolumab, ipilimumab, and tocilizumab.
Immune Checkpoint Inhibitors Potentially Curative for Melanoma
Ten-year follow up from the CheckMate 067 and KEYNOTE-006 trials confirm that patients with advanced melanoma can achieve durable responses from treatment with the PD1 inhibitors nivolumab and pembrolizumab and that a lack of disease progression at 3 years is strong indicator of long-term survival.
Survival Plateau Observed After ICI Therapy in Advanced Melanoma
Patients with advanced melanoma reach a plateau in survival after treatment with immune checkpoint inhibitors (ICIs), according to real-world data published in JAMA Network Open.